Anvisa cancels registration of multi-million dollar therapy and raises regulatory alert

The cancellation of Elevidys' registration by Anvisa, requested by pharmaceutical company Roche itself after data failed to meet conditional requirements, represents a severe blow to the advanced therapies market in Brazil and exposes the regulatory risks of the healthcare sector. This decision comes at a time of extreme economic pressure, marked by a 12-month accumulated IPCA of 4.44% and a monthly variation trend that demands extreme caution in corporate and family capital allocation. The national market operates under the weight of severe liquidity restrictions, with the commercial dollar quoted at R$ 5.1625 and recording a slight retraction of -0.46% over a 30-day horizon.

In the current macroeconomic landscape, monetary rigidity is present with the Selic rate set at 14.00% per year, a stable level that directly impacts the cost of capital for large investments in research and development. Analyzing the exchange rate scenario, the rate of R$ 5.16 reflects a depreciation of -0.03% in the 7-day window, highlighting an environment of relative nominal stability, but with latent volatility in the import costs of high-value-added pharmaceutical and biotechnological inputs.

This news adds to a recent history of negative reports on the portal, consolidating the sixth consecutive record of pessimistic bias in economic and institutional policy agendas, such as the tightening of bank credit and the increase in corporate leverage. From a structural macro perspective, the episode perfectly illustrates the contraction in liquidity and credit cycles, where high-risk and deferred-return projects undergo drastic revisions of financial viability due to the rising cost of new money and the contraction of risk appetite among major global players.